The Australian National Blood Pressure Study was a controlled therapeutic trial of antihypertensive drug treatment in 3427 men and women aged 30-69 years. The subjects were recruited from the general population by community screening. Persons whose average fifth phase diastolic blood pressure (DBP), measured twice on each of two occasions, was within the defined mild range and who had no exclusion factors, were eligible to enter the study. The defined mild range of hypertension was an average DBP of 95-109 mmHg with a systolic blood pressure (SBP) of less than 200 mmHg. The exclusion factors, which included recent treatment for hypertension, any previous stroke, a recent myocardial infarction, abnormal electrocardiographic (ECG) findings or elevation of serum creatinine, ensured that the participants were substantially free from cardiovascular complications of hypertension on entering the study. Eligible subjects who agreed to enter the study were randomly allocated with stratification of age and sex to take either pharmacologically active tablets or matching placebo tablets.
Introduction
The Australian National Blood Pressure Study was a controlled therapeutic trial of antihypertensive drug treatment in 3427 men and women aged 30-69 years. The subjects were recruited from the general population by community screening. Persons whose average fifth phase diastolic blood pressure (DBP), measured twice on each of two occasions, was within the defined mild range and who had no exclusion factors, were eligible to enter the study. The defined mild range of hypertension was an average DBP of 95-109 mmHg with a systolic blood pressure (SBP) of less than 200 mmHg. The exclusion factors, which included recent treatment for hypertension, any previous stroke, a recent myocardial infarction, abnormal electrocardiographic (ECG) findings or elevation of serum creatinine, ensured that the participants were substantially free from cardiovascular complications of hypertension on entering the study. Eligible subjects who agreed to enter the study were randomly allocated with stratification of age and sex to take either pharmacologically active tablets or matching placebo tablets.
All subjects in the study were treated at special clinics for an average period of 4 years. They attended the clinics at 2-week intervals during stabilization and then at 4-month intervals, or more frequently, if at any visit DBP was 110 mmHg or more or SBP was 200 mmHg or more. If at three such successive visits within a 6-week period the blood pressure remained above these thresholds, definitive antihypertensive treatment was given. This was not a trial end point and these subjects, 198 in the placebo group and four in the active group, were kept in the study in their original treatment classification. Any trial end points ( Table 1) that occurred were counted against the trial regimen to which they had been randomized originally.
Correspondence: Rofessor A. E. Doyle, Austin Hospital, Heidelberg, Victoria 3084, Australia. At each 4-month visit, blood pressure was measured, tablet doses were adjusted if necessary and evidence for trial end points and treatment side effects was sought. A full clinical, biochemical and electrocardiogram examination was made annually. Trial end points were reviewed by a special committee unaware of the subject's treatment group and blood pressure. An ECG committee, similarly 'blind', reported on all tracings. The occurrence of any trial end point terminated the subject's participation in the study.
Premature withdrawals
Approximately one-third of each group prematurely stopped the regimen to which they had been randomly allocated. There were no significant differences between the entry characteristics of the subjects in the active and placebo groups in those who stopped prematurely, and the rates of subsequent trial end points were not significantly different between the two groups. Of the 88 subjects lost to follow-up, 42 were in the active Rates are per lo00 person-years'exposure to risk. *P < 0.025; **P < 0.05: '**P < 0.01.
Category
Intention to treat and 46 were in the placebo group. None had been registered as a death in Australia. The fact that in subjects who prematurely stopped their regimen the match between the active and placebo groups in regard to entry characteristics, trial end-point rates, types of end points and reasons for stopping makes it unlikely that factors associated with premature stopping biased the results. As previously stated, patients whose blood pressures rose enough to require definitive treatment remained in the trial in their randomized categories and were not regarded as withdrawals.
Persons who withdrew from the placebo group did so mainly because their physicians commenced regular treatment, whereas persons who withdrew from the active group generally discontinued treatment.
Trial end points
The cumulative occurrence of total trial end points and of all deaths for subjects continuing on their regimen was recorded. Differences between the groups emerged early, and when analysed by life-table analysis, were significant for all trial end points (P < 0.01) and for all deaths (P < 0.05).
Two types of analysis of end points were made. The 'on-treatment' analysis takes into account the experience, before stopping of the 1209 who prematurely stopped their regimen and also that of the 2218 subjects who continued on their trial regimen either until a trial end point occurred or until the end of the study. The 'intention-to-treat' analysis takes into account the person-years' exposure to risk of all 3427 subjects and trial end points that occurred either before or after stopping in the 3339 subjects whose status was known at the end of the trial. In both analyses, the rates of both cardiovascular deaths and trial end points were significantly lower in the active than in the placebo group (Table 2) .
In the on-treatment analysis, the rates of all deaths and of all non-fatal trial end points were significantly lower in the active than in the placebo group (Table 2) . Noncardiovascular deaths were similarly distributed between the two groups.
Over two-thirds of all trial end points were due to ischaemic heart disease. These were predominantly non-fatal events that occurred in similar numbers in both groups. They consisted of myocardial infarctions, episodes of chest pain accompanied by ECG changes, and angina pectoris as assessed by a positive response to the Rose questionnaire (Table 3 ).
In contrast, the incidence of all types of cerebrovascular events was significantly lower in the active than in the placebo group, both for fatal and non-fatal strokes (Table 3 ). There were fewer trial end points in the active than in the placebo groups in men and women considered separately and in those over and under 50 years of age at entry.
The overall death rate in both groups was low. This probably reflects in part at least the exclusion of individuals with evidence of preexisting cardiovascular complications of hypertension. The low rate of death and complications in the placebo treated group may also be due partly to the fact that 198 (12%) of this group whose pressures exceeded 110 mmHg began active treatment although remaining in the placebo group, for the purposes of analysis.
Blood pressures
For each subject, the average of all diastolic pressures recorded after commencing tablets has been estimated. In both active and placebo groups, the average DBP while on tablets was lower than the screening DBP, and the higher the screening pressure, the greater the fall. For each screening DBP class, the fall was greater in the active than in the placebo group ( Table 4) . The relationship between average DBP during the therapeutic regimen and trial end points occurring at each class of blood pressure is shown in Fig. 1 .
In both the active and the placebo groups, increasing DBP during the study was associated with a higher rate of trial end points. At the very lowest blood pressures, the rates in the active and the placebo groups was almost identical. At higher DBP, the rate was higher in the actively treated group than in the placebo treated group, suggesting that if blood pressure is not well controlled, the use of antihypertensive drugs may be associated with an additional risk, presumably due to the drugs themselves. It has to be emphasized that the numbers at the higher DBP in the treated group were small. It is possible that the individuals in this group, who were presumably relatively resistant to drug treatment, may have a worse prognosis than the average hypertensive patient. Either explanation would account for this finding. If the effect is drug related, it appears that it is abolished by effective control of DBP. Fig. 2 also indicates that 87% of the actively treated group had DBP below 94 mmHg, whereas 55% of the placebo group were in this DBP category. This shift away from higher average DBP to pressures at which trial end point rates were lower presumably is responsible for the overall benefit obtained in the active group.
In the placebo group as a whole, there was a fall in diastolic pressure over a period of 3 years (Fig. 2) . Almost half of the control group had DBP below 95 mmHg at 3 years, and 12% had pressures which rose above 110 mmHg. On the average, persons whose DBP fell to below 95 mmHg at 3 years had lower than average entry pressures, and those whose DBP rose above mild limits had higher than average pressures (Table  4 ). In the individual patient, however, there were no characteristics including entry blood pressure level which allowed a prediction to be made as to whether blood pressure would rise or fall. The fact that almost half of those found at screening to have mild hypertension subsequently had falls of blood pressure to normal or near normal levels stresses the need for a period of observation before antihypertensive treatment is initiated.
